Navidea Biopharmaceuticals (NAVB) - NYSEMKT
  • Nov. 3, 2015, 5:30 PM
  • Jul. 30, 2015, 10:07 AM
    • Navidea Biopharmaceuticals (NAVB -3.2%) Q2 results: Revenues: $2.9M (+163.6%); COGS: $0.3M (+22.2%); R&D Expense: $2.3M (-54.9%); SG&A: $4M (-18.4%); Operating Loss: ($3.8M) (+58.7%); Net Loss: ($9.7M) (+4.9%); Loss Per Share: ($0.06) (+14.3%); Quick Assets: $15.8M (+187.3%).
    • 2015 Guidance: Lymphoseek revenue: $10M - 12M.
    | Jul. 30, 2015, 10:07 AM | 8 Comments
  • Jul. 30, 2015, 7:39 AM
    • Navidea Biopharm (NYSEMKT:NAVB): Q2 EPS of -$0.06 misses by $0.02.
    • Revenue of $2.87M (+168.2% Y/Y) beats by $0.69M.
    | Jul. 30, 2015, 7:39 AM
  • Jul. 2, 2015, 9:11 AM
    | Jul. 2, 2015, 9:11 AM | 13 Comments
  • Jun. 11, 2015, 9:09 AM
    • BIND Therapeutics (NASDAQ:BIND) and Navidea Biopharmaceuticals (NYSEMKT:NAVB) subsidiary Macrophage Therapeutics enter into a research collaboration to engineer Accurins with the Manocept targeting platform. After completing the proof-of-concept work, the companies plan to expand the partnership to develop Manocept-linked Accurins for the treatment of cancer.
    • Accurins are nanoparticles that incorporate a therapeutic payload and are designed to have prolonged circulation in the bloodstream thereby providing controlled and timely release of the therapy to diseased tissue or cells.
    • The tilmanocept technology or Manocept, is a platform technology which specifically targets activated macrophages, a type of white blood cell that "eats" cellular debris. Manocept enables the selective binding to a protein found on the surface of disease-associated macrophages called CD206.
    • Macrophages play a key role in many diseases so coupling Accurins to them via CD206 may produce a therapeutic benefit.
    • Financial terms of the collaboration are not disclosed.
    | Jun. 11, 2015, 9:09 AM | 22 Comments
  • Jun. 9, 2015, 9:17 AM
    | Jun. 9, 2015, 9:17 AM | 5 Comments
  • May 12, 2015, 7:55 AM
    • Navidea Biopharmaceuticals (NAVB +1.6%) Q1 results: Revenues: $2.1M (+162.5%); COGS: $0.4M (+100.0%); R&D Expense: $4M (-23.1%); SG&A: $5.5M (+41.0%); Operating Loss: ($7.8M) (+9.3%); Net Loss: ($7.3M) (+37.6%); Loss Per Share: ($0.05) (+37.5%); Quick Assets: $4.9M (-10.9%).
    • 2015 Guidance: Lymphoseek revenue: $10M - 12M.
    | May 12, 2015, 7:55 AM | 1 Comment
  • May 12, 2015, 7:31 AM
    • Navidea Biopharm (NYSEMKT:NAVB): Q1 EPS of -$0.05 misses by $0.02.
    • Revenue of $2.11M (+181.3% Y/Y) misses by $1.16M.
    | May 12, 2015, 7:31 AM | 1 Comment
  • May 11, 2015, 6:37 PM
    • Navidea Biopharmaceuticals (NYSEMKT:NAVB) secures a $60M loan from CRG which it will use to retire its debt from Oxford Finance, support the commercialization of Lymphoseek and general corporate purposes.
    • Under the terms of the loan, Navidea will receive an initial $50M for a term of six years, the first four interest-only, at a 14% interest rate. An additional $10M will be available under certain conditions. After paying off the Oxford debt, the company will have $18M in new capital.
    • In conjunction with the CRG financing, Navidea amends its existing line of credit with Platinum-Montaur Life Sciences that will allow it to remain in place in a subordinated position to the CRG loan. Platinum may convert the company's $7.7M debt into common stock if the average price exceeds $2.53 per share for 10 consecutive trading days. Today's close was $1.35.
    | May 11, 2015, 6:37 PM | 4 Comments
  • May 11, 2015, 5:30 PM
  • Apr. 27, 2015, 11:45 AM
    • As part of its ongoing efforts to divest non-core neuroimaging assets and refocus on the Manocept platform, Lymphoseek and immuno-oncology therapeutics, Navidea Biopharmaceuticals (NAVB +1.3%) terminates its sub-license agreement with Alseres Pharmaceuticals for NAV5001, an imaging agent in Phase 3 development for early detection of Parkinson's disease.
    • Under the terms of the termination agreement, Navidea will transfer all NAV5001-related assets back to Alseres, but will provide clinical support services for NAV5001 on a cost-plus reimbursement basis. It will also receive a milestone payment based on the FDA's approval of NAV5001's New Drug Application (NDA) and a royalty on subsequent commercial sales. Alseres will reimburse Navidea for any maintenance costs of the contract manufacturer retroactive to March 1.
    | Apr. 27, 2015, 11:45 AM | 31 Comments
  • Mar. 5, 2015, 9:15 AM
    | Mar. 5, 2015, 9:15 AM | 2 Comments
  • Mar. 5, 2015, 8:25 AM
    • Navidea Biopharmaceuticals (NAVB -1.2%) Q4 results: Revenues: $2.2M (+340.0%); COGS: $0.3M (+50.0%); R&D Expense: $2.3M (-75.5%); SG&A: $4.1M (+2.5%); Operating Loss: ($4.5M) (+65.6%); Net Loss: ($6.9M) (+50.0%); Loss Per Share: ($0.05) (+50.0%).
    • FY2014 results: Revenues: $6.3M (+472.7%); COGS: $1.6M (+433.3%); R&D Expense: $16.8M (-29.1%); SG&A: $15.5M (+0.1%); Operating Loss: ($27.6M) (+28.1%); Net Loss: ($35.7M) (+16.4%); Loss Per Share: ($0.24) (+31.4%); Quick Assets: $5.5M (-83.3%).
    • 2015 Guidance: Lymphoseek revenue: $10M - 12M.
    | Mar. 5, 2015, 8:25 AM | 3 Comments
  • Mar. 5, 2015, 7:33 AM
    • Navidea Biopharm (NYSEMKT:NAVB): Q4 EPS of -$0.05 in-line.
    • Revenue of $2.2M (+307.4% Y/Y) beats by $0.1M.
    • Shares +16.67% PM.
    | Mar. 5, 2015, 7:33 AM | 15 Comments
  • Mar. 5, 2015, 7:22 AM
    • Navidea (NYSEMKT:NAVB) to receive $2M upfront payment on exclusive sublicense agreement for the commercialization and distribution of Lymphoseek 250 microgram kit in the EU.
    • NAVB is eligible to receive additional milestone payments of up to $5M, and royalties on EU net sales.
    • Lymphoseek is a receptor-targeted, radiopharmaceutical imaging agent approved by the FDA in 2013 and by the EU in November 2014. It is approved in Europe for imaging and intraoperative detection of sentinel lymph nodes in patients with breast cancer, melanoma, or localized squamous cell carcinoma of the oral cavity.
    | Mar. 5, 2015, 7:22 AM | 7 Comments
  • Mar. 4, 2015, 5:30 PM
    | Mar. 4, 2015, 5:30 PM | 4 Comments
Company Description
Navidea Biopharmaceuticals, Inc. develops and commercializes precision diagnostics and radiopharmaceutical agents, which are intended to improve diagnostic accuracy, clinical decision-making and patient care. Its current radiopharmaceutical development programs include Lymphoseek, AZD4694 and... More
Sector: Healthcare
Industry: Medical Appliances & Equipment
Country: United States